GANX Gain Therapeutics, Inc.
$1.75▲ +2.34%
Healthcare
Other
After hours
$1.75▲ +0.04%
Sep 11, 7:58 PM ET
Volume 223.6K
Avg Volume (10D) 326.3K
Key Metrics & Fundamentals
Market Cap
$76.38M
P/E Ratio
–
Div Yield
–%
52W Range
1.53 - 4.34
% vs 50 MA
-4.50%
% vs 200 MA
-18.51%
RSI-14
43.4
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.80
Free Cash Flow
-$4.68M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.70M
COGS
–
Operating Exp
$4.68M
Operating Income
-$4.68M
EBIT
-$4.68M
Pretax Income
-$4.57M
Net Income
-$4.68M
EPS (Diluted)
-0.11
Price & Volume History
Loading chart…
Recent News
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Aug 25, 2026 11:00 AM
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
GlobeNewswire · Aug 11, 2026 11:00 AM
Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Terenzio Ignoni as COO
MT Newswires · Jul 16, 2026 12:21 PM
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
GlobeNewswire · Jul 16, 2026 11:00 AM
Why Is GANX Stock Rallying 22% After Hours?
Stocktwits · Jun 29, 2026 9:34 PM
Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease
MT Newswires · Jun 29, 2026 8:36 PM
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
GlobeNewswire · Jun 29, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See GANX's money flow as a full page
Social Sentiment
Avg +0.00 · 2 posts
TradeEarningsDiscussionUnderstanding EPS and P/E in my analysis?
r/investing · Nov 13, 2025
The author views the trade as a win, indicating a positive sentiment.
positive
+0.60
GANX: a $90 million company becoming a >$900 million company by slowing, stopping, and reversing Parkinson’s disease.
r/stocks · Nov 11, 2025
The comments express significant skepticism and warnings about the stock, suggesting it's a 'pump and dump' or a risky investment.
negative
-0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.